1. Pink Sheet
  2. >>Market Access

‘Most Favored Nation’ Pricing Data May Be Long-Term Impact Of Last-Minute Rule

 
• By Michael McCaughan

Rushed final rule seeking to impose draconian cuts on drug reimbursement rates in the Medicare Part B program is certain to face legal and political obstacles. But the data included on international price benchmarks will still have an impact.

Even if the most favored nation policy is never implemented, the rule shows how the prices of many drugs in Medicare Part B measure up to other countries. • Source: Shutterstock

The US Medicare Part B drug reimbursement system remains a unique cross between low-hanging fruit and third-rail status in the drug pricing debate.

On the one hand, the system to pay for physician-administered therapies is a rare case where the federal government pays...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Medicare

More from Government Payers